Three promising studies featuring psilocybin, LSD and MDMA have shown signs of improved brain function.
The world’s first postgraduate course on psychedelics has been launched at the University of Exeter – an interdisciplinary programme for healthcare workers, therapists and others to...
Awakn Life Sciences and the University of Exeter (UoE) are collaborating to put in place a framework for a Phase 3 trial exploring the use of...
Filament Health and PharmAla Biotech Holdings Inc.
With a high demand for psychedelic facilitators, Cybin Inc.
Patients with Major Depressive disorder (MDD) have been shown to achieve remission within three months following treatment with SPL026 combined with supportive therapy in Small Pharma’s...
In a partnership that has been described as “an important step to reintroduce psychedelics into society”, Dimensions and the New Health Club are joining together to...
With years of experience in developing cannabinoid medicines, Australia-based MGC Pharmaceuticals will now be branching into psychedelic medicine development.
The Dutch Parliament has established an independent State Commission to research the legal status of MDMA and provide advice on its medical use.
Study participants demonstrated a durable response at least six months, and in some cases a year or more, after their final MDMA-assisted therapy session during the...